Antonio Milici - GeneThera Chairman
| GTHR Stock | USD 0.01 0.00 0.00% |
Chairman
Dr. Antonio Milici, M.D., Ph.D., is the Chairman of the Board, Chief Executive Officer, Chief Scientific Officer of GeneThera, Inc. Dr. Milici founded GeneThera, Inc. in 1998 and has served as its Chairman and CEO since inception. Prior to founding GeneThera, Dr. Milici served as CEO and President of Genetrans, Inc., a genetic diagnostic company from 1993 to 1998. Dr. Milici was also an assistant professor in the department of Molecular Pathology at the University of Texas M.D. Anderson Cancer Center.
| Age | 59 |
| Phone | 720 587 5100 |
| Web | https://www.genethera.net |
GeneThera Management Efficiency
The company has return on total asset (ROA) of (95.3798) % which means that it has lost $95.3798 on every $100 spent on assets. This is way below average. GeneThera's management efficiency ratios could be used to measure how well GeneThera manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Abe Schwartz | Covalon Technologies | N/A | |
Management Performance
| Return On Asset | -95.38 |
GeneThera Leadership Team
Elected by the shareholders, the GeneThera's board of directors comprises two types of representatives: GeneThera inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeneThera. The board's role is to monitor GeneThera's management team and ensure that shareholders' interests are well served. GeneThera's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeneThera's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bruce Winsett, Director | ||
| Jorgen Frandsen, Director | ||
| Antonio MD, Chairman, Founder | ||
| Jeremiah Bartley, Director | ||
| Fred Oeschger, Director | ||
| Antonio Milici, Chairman of the Board, CEO, Chief Scientific Officer | ||
| Tannya Irizarry, Chief Admin. Officer, Interim CFO, Interim Principal Accounting Officer and Secretary |
GeneThera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GeneThera a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -95.38 | |||
| Current Valuation | 1.44 M | |||
| Shares Outstanding | 35.33 M | |||
| Shares Owned By Insiders | 17.99 % | |||
| Price To Earning | (0.17) X | |||
| EBITDA | (1 M) | |||
| Net Income | (1.01 M) | |||
| Cash And Equivalents | 140.1 K | |||
| Total Debt | 806.87 K | |||
| Book Value Per Share | (0.24) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GeneThera in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GeneThera's short interest history, or implied volatility extrapolated from GeneThera options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GeneThera. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the GeneThera information on this page should be used as a complementary analysis to other GeneThera's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for GeneThera Pink Sheet analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |